NIOX NIOX Group Plc

LSE · GB · Healthcare · Medical Devices · niox.com

67.40GBp+0.90%Mkt Cap: 308.33M $P/E: 33.70Today

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and poi…

Industry Peers

Medical Devices

Screen all

ABT

Abbott Laboratories Common Stock

$169.83BUSDP/E 31.6

MDT

Medtronic plc. Ordinary Shares

$110.49BUSDP/E 21.2

SYK

Stryker Corporation Common Stock

$105.65BUSDP/E 28.5

BSX

Boston Scientific Corporation Common Stock

$61.74BUSDP/E 17.2

Edwards Lifesciences Corporation Common Stock

$49.03BUSDP/E 50.7

SHL

Siemens Healthineers AG

$46.06BUSDP/E 19.2

DXCM

DexCom, Inc. - Common Stock

$32.21BUSDP/E 33.7

GEHC

GE HealthCare Technologies Inc. - Common Stock

$29.24BUSDP/E 14.8

PHG

Koninklijke Philips N.V. NY Registry Shares

$23.38BUSDP/E 18.5

PHIA

Koninklijke Philips N.V.

$22.58BUSDP/E 18.5

STE

STERIS plc (Ireland) Ordinary Shares

Zimmer Biomet Holdings, Inc. Common Stock

$16.84BUSDP/E 21.4

PEN

Penumbra, Inc. Common Stock

$12.51BUSDP/E 77.8

TXG

10x Genomics, Inc. - Common Stock

$12.18BUSD

SNN

Smith & Nephew SNATS, Inc. Common Stock

$11.06BUSDP/E 18.0

GMED

Globus Medical, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc. Class A Common Stock

$9.88BUSDP/E 45.0

GKOS

Glaukos Corporation Common Stock

$9.66BUSD

Key Statistics

Company

Market Cap308.33M USD

Enterprise Value286.85M USD

Revenue (TTM)51.63M USD

Gross Profit36.63M USD

Net Income (TTM)7.61M USD

Revenue/Share0.11 GBp

Last Price67.40 GBp

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees97

CountryGB

SectorHealthcare

IndustryMedical Devices

ISIN—

Valuation

P/E (Trailing)33.70

P/E (Forward)18.96

PEG—

EV/EBITDA18.58

EV/Revenue5.56

P/S5.92

P/B4.12

EPS (TTM)0.02

EPS (Forward)0.04

52W Range

53.8461% of range76.00

52W High76.00 GBp

52W Low53.84 GBp

Profitability

Gross Margin69.20%

Oper. Margin22.92%

EBITDA Margin29.90%

Profit Margin14.37%

ROE10.36%

ROA9.19%

Growth

Revenue Growth-4.80%

Earnings Growth-0.70%

Cash Flow & Leverage

Operating CF16.74M USD

CapEx (TTM)1.63M USD

FCF Margin17.26%

FCF Yield2.89%

Net Debt-17.50M USD

Net Debt/EBITDA-1.13

Balance Sheet

Debt/Equity0.01

Current Ratio4.60

Quick Ratio3.32

Book Value/Sh0.16 GBp

Cash/Share0.04 GBp

Dividends

Fwd Div Rate0.02 GBp

Trail. Div Rate0.02 GBp

Div. Yield2.32%

5Y Avg Yield—

Payout Ratio95.09%

Ex-Div DateMay 21, 2026

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)82.40 GBp

Upside (mean)+22.3%

Target Range77.00 GBp – 86.00 GBp

77.00+22.3% to mean86.00

# Analysts5

Ownership

Shares Out.420.87M

Float330.28M

Insiders20.93%

Institutions65.91%

Technical

SMA 5065.86 (+2.3%)

SMA 20062.84 (+7.3%)

Beta-0.08

S&P 52W Chg14.58%

Avg Vol (30d)527.52K

Avg Vol (10d)430.14K

Technical Indicators

RSI (14)51.4

MACD0.4222

MACD Signal0.5431

MACD Hist.-0.1209

BB Upper68.88 GBp

BB Middle66.71 GBp

BB Lower64.54 GBp

BB Width6.50%

ATR (14)2.581 GBp

Vol Ratio (20d)0.34x